UVA Radiation Enhances Lomefloxacin-Mediated Cytotoxic, Growth-Inhibitory and Pro-Apoptotic Effect in Human Melanoma Cells through Excessive Reactive Oxygen Species Generation.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Nov 2020
Historique:
received: 22 08 2020
revised: 19 11 2020
accepted: 20 11 2020
entrez: 1 12 2020
pubmed: 2 12 2020
medline: 6 3 2021
Statut: epublish

Résumé

Melanoma, the most dangerous type of cutaneous neoplasia, contributes to about 75% of all skin cancer-related deaths. Thus, searching for new melanoma treatment options is an important field of study. The current study was designed to assess whether the condition of mild and low-dose UVA radiation augments the lomefloxacin-mediated cytotoxic, growth-inhibitory and pro-apoptotic effect of the drug in melanoma cancer cells through excessive oxidative stress generation. C32 amelanotic and COLO829 melanotic (BRAF-mutant) melanoma cell lines were used as an experimental model system. The combined exposure of cells to both lomefloxacin and UVA irradiation caused higher alterations of redox signalling pathways, as shown by intracellular reactive oxygen species overproduction and endogenous glutathione depletion when compared to non-irradiated but lomefloxacin-treated melanoma cells. The obtained results also showed that lomefloxacin decreased both C32 and COLO829 cells' viability in a concentration-dependent manner. This effect significantly intensified when melanoma cells were exposed to UVA irradiation and the drug. For melanoma cells exposed to lomefloxacin or lomefloxacin co-treatment with UVA irradiation, the concentrations of the drug that decreased the cells' viability by 50% (EC

Identifiants

pubmed: 33255659
pii: ijms21238937
doi: 10.3390/ijms21238937
pmc: PMC7728064
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Cytotoxins 0
Fluoroquinolones 0
Reactive Oxygen Species 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
lomefloxacin L6BR2WJD8V

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-037/K/9/O

Références

Anticancer Res. 2017 Nov;37(11):6407-6413
pubmed: 29061826
Toxicol In Vitro. 2020 Aug;66:104884
pubmed: 32437906
Clin Exp Ophthalmol. 2007 Aug;35(6):566-77
pubmed: 17760640
J Dtsch Dermatol Ges. 2014 Jun;12(6):467-72
pubmed: 24825465
Toxicol In Vitro. 2019 Mar;55:75-92
pubmed: 30528372
Cell Div. 2009 Jul 03;4:13
pubmed: 19575778
Eur J Pharmacol. 2018 Sep 15;835:94-107
pubmed: 30086267
J Med Life. 2014 Oct-Dec;7(4):572-6
pubmed: 25713625
Oncotarget. 2015 Mar 30;6(9):7195-208
pubmed: 25749517
J Invest Dermatol. 2015 Aug;135(8):1929-1933
pubmed: 26174532
Biochim Biophys Acta. 2006 Feb;1763(2):214-25
pubmed: 16458373
J Invest Dermatol. 2014 Aug;134(8):2080-2085
pubmed: 24759085
J Biol Chem. 2007 May 11;282(19):14337-47
pubmed: 17374608
Mol Oncol. 2016 Jan;10(1):73-84
pubmed: 26365896
J Invest Dermatol. 2015 Feb;135(2):352-358
pubmed: 25142731
Bioorg Med Chem. 2019 Jul 15;27(14):3005-3060
pubmed: 31182257
Clin Infect Dis. 2005 Jul 15;41 Suppl 2:S144-57
pubmed: 15942881
Int J Dermatol. 2012 Apr;51(4):420-6
pubmed: 22435430
J Photochem Photobiol B. 1998 Aug 21;45(1):51-9
pubmed: 9819899
Free Radic Res. 2008 Aug;42(8):689-706
pubmed: 18671159
Int J Mol Sci. 2018 Feb 02;19(2):
pubmed: 29393886
J Biol Chem. 2006 Oct 6;281(40):29542-57
pubmed: 16857677
J Invest Dermatol. 2016 Nov;136(11):2277-2286
pubmed: 27427486
Biomed Pharmacother. 2019 Mar;111:934-946
pubmed: 30841473
Science. 2014 Nov 21;346(6212):945-9
pubmed: 25414302
Int J Oncol. 2018 May;52(5):1727-1737
pubmed: 29532860
Cancers (Basel). 2011 Mar 11;3(1):1285-310
pubmed: 24212662
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053584
Cells. 2019 Nov 24;8(12):
pubmed: 31771278
J Photochem Photobiol B. 2005 Apr 4;79(1):25-34
pubmed: 15792876
Int J Pharm. 2016 Aug 20;510(1):240-9
pubmed: 27282536
Biochim Biophys Acta. 2011 Jun;1807(6):735-45
pubmed: 21453675
Cell Death Dis. 2016 Jun 09;7(6):e2253
pubmed: 27277675
Chemistry. 2008;14(2):653-63
pubmed: 17943704
Chem Soc Rev. 2003 Jul;32(4):238-50
pubmed: 12875030

Auteurs

Artur Beberok (A)

Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.

Zuzanna Rzepka (Z)

Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.

Jakub Rok (J)

Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.

Klaudia Banach (K)

Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.

Dorota Wrześniok (D)

Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH